{"disease":{"id":"treatment-of-mild-to-moderate-covid-19","name":"treatment of mild to moderate covid 19"},"drugs":{"marketed":[{"drug_id":"nirmatrelvir","indication_name":"Treatment of mild-to-moderate COVID-19","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Paxlovid (Copackaged)","generic_name":"nirmatrelvir","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":60,"revenue":"2362.0","mechanism":"Paxlovid works by binding to the main protease enzyme of the SARS-CoV-2 virus, preventing it from replicating."},{"drug_id":"nirmatrelvir-ritonavir","indication_name":"Treatment of mild to moderate COVID-19 in adults and pediatric patients (5 years of age and older) who weigh at least 40 kg.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"nirmatrelvir-ritonavir","generic_name":"nirmatrelvir-ritonavir","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 protease enzyme","drug_class":"Protease inhibitor","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"part-a-atm-avi-single-dose-cohorts-1-4","indication_name":"Treatment of COVID-19 in adults and pediatric patients (12 years of age and older) who are at high risk of progression to severe COVID-19, including those who are hospitalized due to COVID-19 or who have mild to moderate COVID-19 with at least one risk factor for progression to severe COVID-19 (e.g., older age, certain chronic medical conditions)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part A: ATM-AVI Single Dose, Cohorts 1-4","generic_name":"part-a-atm-avi-single-dose-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"Monoclonal antibody","quality_score":22,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"nirmatrelvir","guideline_body":"FDA label","recommendation":"PAXLOVID is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null}],"source":"Drug Landscape verified database"}